Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Eagle Pharmaceuticals (EGRX)

Eagle Pharmaceuticals (EGRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 8,445
  • Shares Outstanding, K 12,987
  • Annual Sales, $ 316,610 K
  • Annual Income, $ 35,640 K
  • EBIT $ 41 M
  • EBITDA $ 55 M
  • 60-Month Beta 0.62
  • Price/Sales 0.11
  • Price/Cash Flow 0.18
  • Price/Book 0.04
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 1.18
  • Most Recent Earnings N/A on 08/08/23
  • Next Earnings Date 10/01/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 396.51%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0025 +25,912.00%
on 10/28/24
1.1000 -40.88%
on 10/18/24
+0.0503 (+8.38%)
since 10/15/24
3-Month
0.0025 +25,912.00%
on 10/28/24
5.4500 -88.07%
on 08/29/24
-3.3297 (-83.66%)
since 08/15/24
52-Week
0.0025 +25,912.00%
on 10/28/24
9.1018 -92.86%
on 11/20/23
-8.1797 (-92.64%)
since 11/15/23

Most Recent Stories

More News
Eagle Announces Update on Delisting from Nasdaq and SEC Deregistration

EGRX : 0.6503 (-7.17%)
Eagle Pharmaceuticals Appoints Christopher Krawtschuk as Chief Financial Officer

EGRX : 0.6503 (-7.17%)
Eagle Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan

EGRX : 0.6503 (-7.17%)
Eagle Pharmaceuticals: Q2 Earnings Snapshot

Eagle Pharmaceuticals: Q2 Earnings Snapshot

EGRX : 0.6503 (-7.17%)
Eagle Pharmaceuticals: Q1 Earnings Snapshot

Eagle Pharmaceuticals: Q1 Earnings Snapshot

EGRX : 0.6503 (-7.17%)
Eagle Pharmaceuticals: Q4 Earnings Snapshot

Eagle Pharmaceuticals: Q4 Earnings Snapshot

EGRX : 0.6503 (-7.17%)
Eagle Pharmaceuticals: Q3 Earnings Snapshot

Eagle Pharmaceuticals: Q3 Earnings Snapshot

EGRX : 0.6503 (-7.17%)
Eagle Pharmaceuticals (EGRX) Q2 2022 Earnings Call Transcript

EGRX earnings call for the period ending June 30, 2022.

EGRX : 0.6503 (-7.17%)
Eagle Pharmaceuticals Reports Second Quarter 2022 Results

•   Q2 2022 net loss was $(0.74) per basic and diluted share and adjusted non-GAAP net income was $1.58 per basic and $1.56 per diluted share •   Total...

EGRX : 0.6503 (-7.17%)
Eagle Pharmaceuticals Takes Equity Stake in, with Option to Acquire, Enalare Therapeutics to Advance Global Development of ENA-001, a Novel Agnostic Respiratory Stimulant

-- ENA-001 is currently in development for: post-operative respiratory depression, community drug overdose, and Apnea of Prematurity -- -- Approval for...

EGRX : 0.6503 (-7.17%)

Business Summary

Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102,...

See More

Key Turning Points

3rd Resistance Point 0.9399
2nd Resistance Point 0.8819
1st Resistance Point 0.7661
Last Price 0.6503
1st Support Level 0.5923
2nd Support Level 0.5343
3rd Support Level 0.4185

See More

52-Week High 9.1018
Fibonacci 61.8% 5.6259
Fibonacci 50% 4.5521
Fibonacci 38.2% 3.4784
Last Price 0.6503
52-Week Low 0.0025

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar